Results 161 to 170 of about 7,143 (286)

Challenges in Academic Authorship and Citation Metrics: Navigating Inflation, Biases, and the Rise of Evidence Synthesis. [PDF]

Indian J Community Med
Bhattacharya S, Bhattacharjee S, Panigrahi SK, Datta A, Kundu S, Das I, Ganguly A.   +6 more
europepmc   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, EarlyView.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source

Why We Don't Use Guest Editors: A Publisher's Perspective. [PDF]

Blockchain Healthc Today
Cenaj T.
europepmc   +1 more source

The Hirsch-index in self-citation rates with articles in Medicine (Baltimore): Bibliometric analysis of publications in two stages from 2018 to 2021. [PDF]

Medicine (Baltimore), 2022
Liu MY, Chien TW, Chou W.
europepmc   +1 more source

Establishment of a humanized patient‐derived xenograft mouse model of high‐grade serous ovarian cancer for preclinical evaluation of combination immunotherapy

Molecular Oncology, EarlyView.
We have established a humanized orthotopic patient‐derived xenograft (Hu‐oPDX) mouse model of high‐grade serous ovarian cancer (HGSOC) that recapitulates human tumor–immune interactions. Using combined anti‐PD‐L1/anti‐CD73 immunotherapy, we demonstrate the model's improved biological relevance and enhanced translational value for preclinical ...
Luka Tandaric, Line Bjørge, Martine Rott Lode, Cecilie Fredvik Torkildsen, Pia Aehnlich, Rammah Elnour, Daniela Elena Costea, Lars Andreas Akslen, Liv Cecilie Vestrheim Thomsen, Emmet McCormack, Katrin Kleinmanns   +10 more
wiley   +1 more source

Cartels

, 2005
Australian Competition and Consumer Commission webpage describing cartels and how the ACCC identifies and deal with them.

core  

Conflict and its global health consequences: a decolonial call to action. [PDF]

BMJ Nutr Prev Health
Gamlin J, Ahmad A.
europepmc   +1 more source

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

Cartels uncovered. [PDF]

How many cartels are there? The answer is important in assessing the need for competition policy. We present a Hidden Markov Model that answers the question, taking into account that often we do not know whether a cartel exists in an industry or not.
Steen, Frode, Hyytinen, Ari, Toivanen, Otto   +2 more
core  

Artificial Intelligence as a Safeguard for Clinical Scientific Integrity: A Human-AI Hybrid Model for Medical Peer Review. [PDF]

J Clin Med
Dore MP, Merola E, Lasaracina G, Pes GM.
europepmc   +1 more source